Assessment of feasibility of actigraphy as a measure of clinical change in response to an experimental interventional treatment in adolescents and adults with autism spectrum disorder
The observed correlations suggest there may be alignment between some generalized features of actigraphy and core and associated domains of ASD. The clinical utility of actigraphy as a biomarker of clinically relevant outcomes in ASD requires further study. Actigraphy may provide supportive evidence of treatment outcome, providing clinical context, or as a objective behavioral measure (e.g., of sleep or activity level) when combined with more traditional clinical outcome measures.
Authors
- Matthew Boice (ORCID: https://orcid.org/0000-0002-3045-8704)
- Matthew Klein
- S. E. Bryant
- Srinivasan Vairavan (ORCID: https://orcid.org/0000-0001-7975-8436)
- Gahan Pandina (ORCID: https://orcid.org/0000-0003-0050-3575)
- Martine De Meyer (ORCID: https://orcid.org/0000-0003-2002-6163)
- Abi Bangerter
Institutions
- Rutgers, The State University of New Jersey (US)
- Janssen (United States) (US)
Publication Details
- Journal
- Frontiers in Psychiatry
- Published
- 2025-05-23
- DOI
- https://doi.org/10.3389/fpsyt.2025.1570611
- Primary Topic
- Autism Spectrum Disorder Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Janssen Pharmaceuticals